Sitero has expanded its leadership team to support the expected rapid growth of its business.

Prestigious Annual Prize Is Worth $35,000

The Sternfels Prize winner was selected for her novel hypothesis titled 'Experimental Medicine Approach to Optimize Diabetes Treatments'

Annual Prize of $35,000 Awarded to Diabetes Research Proposal

This three-part webinar series reviews the key considerations for design and conduct of a development plan for a monoclonal antibody (mAb) product.

Bringing a drug from discovery to market is an expensive and time-consuming business. Every drug that fails comes with a cost which could be both reputational and financial. Keeping your development program on track is therefore critical to success.

Join this webinar for a discussion of the most common medical communications business challenges and potential solutions. This event will also feature a live demonstration of how patient-centric medical communications technology can be leveraged to streamline and optimize medical inquiry fulfillment, adverse event reporting and product complaint management.

Annual Prestigious Prize Worth $35,000 Drives Critical Research Area

Pharmaceutical development is inherently risky. To develop a molecule that has a desired, efficacious, but safe, effect in humans is a remarkable achievement considering the statistics.

CNS drug developers have to focus on physical safety and efficacy first, especially when developing products for rare disorders or diagnoses that are often unresponsive to other therapies. Although these products rarely have notable CNS mediated side effects, they fall under the FDA's requirement for an abuse potential assessment because they cross the blood-brain barrier.

Presenters will focus on the role of an abuse potential assessment (also referred to as the Controlled Substances Act 8-factor analysis) in the development of cannabinoid products and how it relates to the U.S. scheduling process, and related interactions with the FDA and DEA

Applies Heart-on-a-chip Biowire™ Technology for Cardiac Disease Drug Discovery

The 6th Annual Pharmacovigilance & Risk Management Strategies 2016 brings together Pharmacovigilance and Drug Safety Officers, EU and National Regulatory, Clinical Risk-Benefit Groups, Regulatory Affairs Officers, Consultancies, Local Medicines Authorities, CROs and others.

Stottler Henke Associates, Inc. today announced the immediate availability of an enhanced version of its DataMontage™ software for rapid visual analysis of complex, time-oriented data. DataMontage 4.0 introduces dozens of new features that enable analysts to visualize data more flexibly and interactively.

Sentrx continues to add to its Business Development staff by hiring three new outstanding solution oriented individuals.

Sentrx discusses the importance of outsourcing data monitoring to a sole entity.

Sentrx, industry leader in providing outsourced drug safety solutions, comprehensive pharmacovigilance solutions and data management services, comments on new E.U. Regulations.

Industry Leading Experts Set to Speak at the Marcus Evans 2nd Global Pharmacovigilance & Adverse Event Reporting Conference

Leading provider of Oracle's clinical trial, data, and dug safety software will discuss why and how Empirica Topics should be implemented and used to strengthen an organization's pharmacovigilance systems and processes.

Information-dense interactive displays help analysts review and interpret complex, time-oriented data quickly and consistently

Synowledge announced today that Dr. Seema Jaitly, Director, EU PV and Risk Management, QPPV will be hosting a night of dinner and discussion on behalf of Synowledge.